Alpha-4 beta-2 nicotinic acetylcholine receptor (3:2 stoichiometry) (α4β2 nAChR (3:2))

The alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel and the most prevalent nAChR subtype in the mammalian central nervous system (Gotti et al., 2006, CNS Neurol Disord Drug Targets). It exists in two distinct functional stoichiometries: the (α4)2(β2)3 form, which possesses high affinity for nicotine, and the (α4)3(β2)2 form, which exhibits lower agonist affinity but higher calcium permeability and distinct pharmacological properties (Moroni et al., 2006, J Physiol). This specific (α4)3(β2)2 stoichiometry is a key regulator of dopamine release in the reward circuitry and is a primary target for smoking cessation therapies (Exley et al., 2011, J Neurosci). Beyond addiction, α4β2 receptors are involved in cognitive functions such as attention and memory, and their dysfunction is linked to neurodegenerative diseases like Alzheimer's and Parkinson's (Gotti et al., 2006). Mutations in the subunits of this receptor are also associated with Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) (Steinlein et al., 1995, Nat Genet). Pharmacological targeting of α4β2 receptors, through agonists or partial agonists like varenicline, is a primary strategy for smoking cessation (Rollema et al., 2007, Neuropharmacology). Additionally, positive allosteric modulators and subtype-selective ligands are being explored for treating cognitive deficits and mood disorders. The (α4)3(β2)2 stoichiometry is particularly interesting because its expression levels can be altered by chronic nicotine exposure, contributing to the neuroadaptive changes seen in addiction (Gotti et al., 2009, Prog Neurobiol).

Other names

(alpha4)3(beta2)2 nicotinic receptorLow-affinity alpha4beta2 nAChRLS-alpha4beta2 nAChRCHRNA4-CHRNB2 (3:2) receptorAlpha4(3)beta2(2) nicotinic acetylcholine receptor

Agonism, partial agonism, or allosteric modulation of the pentameric ion channel to regulate cationic influx (Na+, K+, Ca2+) and subsequent neurotransmitter release.